Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (906)	12/1/1997 1:14:00 AM
From: KurtVedder	Read Replies (2) \| Respond to of 1359

From the MF Board: On pp. 115 in Money magazine (1998 Forecast Issue), Mr. Richare Frankel from DL&J listed SPDRs, DELL, and IPIC as his top picks for 1998. His comments on IPIC is as follows:"...Fears about potential liability lawsuits have dragged the stock down 64% from its 97 peak of almost $33. But Frankel says Interneuron has limited liability, ample insurance, $140 millon in cash and several other major drugs now undergoing clinical trials that support his 12-month target price of $22, and 83% rebound form here ($12)".

To: NeuroInvestment who wrote (906)	12/1/1997 3:53:00 PM
From: Pancho Villa	Read Replies (2) \| Respond to of 1359

Neuro you said: >>However,Janssen pulled its drug from AC consideration because its data was so weak, they are now conducting a very large supplemental Ph III. This took the time pressure off IPIC. Keep in mind that October would have been a monumental task to complete,with some risk of missing something....officially IPIC has always said it aimed to file by year-end, and they have taken a little extra time to make sure there are no loopholes or flaws, that their NDA file ...I would not be surprised to have the filing within the next two weeks. NeuroInvestment<< Correct me if I am mistaken but one of the reasons for the delay may be that IPIC is also running extra studies on citicoline as the latest phase III results were weak and inconclusive (Some rather creative a posteriori interpretation/manipulation of results was need to report some positive news on inconclusive data - this is discussed in some of my earlier posts). IMO, IPIC is under a scenario similar to Janssen's, with citicoline also being a weak drug. You see unfortunately stroke is a very challenging condition to treat effectively. The evidence so far is that several expensive drugs tested have not been found to be any more effective than inexpensive generic drugs [which are not very effective either!]. If we had any MD's in this thread [I am not one] perhaps they could enlighten the groupin this area. Pancho PS: I take it that the detailed information on IPIC's rationale and strategic thinking you provide comes from their PR department and that you are getting it in your role as analyst/investor/letter writer. In the event you were to be a spokesperson for IPIC, that is fine with me but IMO this is something you should disclose to the group.